Meta-analysis Confirms CR1, CLU, and PICALM As Alzheimer Disease Risk Loci and Reveals Interactions with APOE Genotypes

Objectives: To determine whether genotypes at CLU, PICALM, and CR1 confer risk for Alzheimer disease (AD) and whether risk for AD associated with these genes is influenced by apolipoprotein E (APOE) genotypes.

Design: Association study of AD and CLU, PICALM, CR1, and APOE genotypes.

Setting: Academic research institutions in the United States, Canada, and Israel.

Participants: Seven thousand seventy cases with AD, 3055 with autopsies, and 8169 elderly cognitively normal controls, 1092 with autopsies, from 12 different studies, including white, African American, Israeli-Arab, and Caribbean Hispanic individuals.

Results: Unadjusted, CLU (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.85-0.96 for single-nucleotide polymorphism [SNP] rs11136000), CR1 (OR, 1.14; 95% CI, 1.07-1.22; SNP rs3818361), and PICALM (OR, 0.89; 95% CI, 0.84-0.94, SNP rs3851179) were associated with AD in white individuals. None were significantly associated with AD in the other ethnic groups. APOE ε4 was significantly associated with AD (ORs, 1.80-9.05) in all but 1 small white cohort and in the Arab cohort. Adjusting for age, sex, and the presence of at least 1 APOE ε4 allele greatly reduced evidence for association with PICALM but not CR1 or CLU. Models with the main SNP effect, presence or absence of APOE ε4, and an interaction term showed significant interaction between presence or absence of APOE ε4 and PICALM.

Conclusions: We confirm in a completely independent data set that CR1, CLU, and PICALM are AD susceptibility loci in European ancestry populations. Genotypes at PICALM confer risk predominantly in APOE ε4-positive subjects. Thus, APOE and PICALM synergistically interact.

Citing Articles

A Massively Parallel CRISPR-Based Screening Platform for Modifiers of Neuronal Activity.

Boggess S, Gandhi V, Tsai M, Marzette E, Teyssier N, Yu-Ying Chou J bioRxiv. 2025; .

PMID: 39990495 PMC: 11844385. DOI: 10.1101/2024.02.28.582546.

Ramp sequence may explain synonymous variant association with Alzheimer's disease in the Paired Immunoglobulin-like Type 2 Receptor Alpha ().

Miller J, Brandon J, McKinnon L, Sabra H, Lucido C, Gonzalez Murcia J bioRxiv. 2025; .

PMID: 39829933 PMC: 11741268. DOI: 10.1101/2025.01.06.631528.

Brain aging and Alzheimer's disease, a perspective from non-human primates.

Isidro F Aging (Albany NY). 2024; 16(20):13145-13171.

PMID: 39475348 PMC: 11552644. DOI: 10.18632/aging.206143.

Editorial: Meeting new challenges in translationally relevant neurodegenerative disease research.

Latimer C, Quadri Z, Cook D Front Neurosci. 2024; 18:1453770.

PMID: 39238927 PMC: 11374760. DOI: 10.3389/fnins.2024.1453770.

Investigating CR1 as an indicated Gene for mild cognitive impairment in type 2 diabetes mellitus.

Zhou X, Wang S, Yu D, Niu T Diabetol Metab Syndr. 2024; 16(1):206.

PMID: 39182129 PMC: 11344402. DOI: 10.1186/s13098-024-01449-y.

References

Pastor P, Roe C, Villegas A, Bedoya G, Chakraverty S, Garcia G . Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol. 2003; 54(2):163-9. DOI: 10.1002/ana.10636. View

Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan M . Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008; 83(5):623-32. PMC: 2668052. DOI: 10.1016/j.ajhg.2008.10.008. View

Rogaev E, Sherrington R, Rogaeva E, Levesque G, Ikeda M, Liang Y . Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995; 376(6543):775-8. DOI: 10.1038/376775a0. View

Wijsman E, Pankratz N, Choi Y, Rothstein J, Faber K, Cheng R . Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011; 7(2):e1001308. PMC: 3040659. DOI: 10.1371/journal.pgen.1001308. View

Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-3. DOI: 10.1126/science.8346443. View

Hulette C, Welsh-Bohmer K, Murray M, Saunders A, Mash D, McIntyre L . Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998; 57(12):1168-74. DOI: 10.1097/00005072-199812000-00009. View

Reiman E, Webster J, Myers A, Hardy J, Dunckley T, Zismann V . GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007; 54(5):713-20. PMC: 2587162. DOI: 10.1016/j.neuron.2007.05.022. View

Carrasquillo M, Zou F, Pankratz V, Wilcox S, Ma L, Walker L . Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet. 2009; 41(2):192-8. PMC: 2873177. DOI: 10.1038/ng.305. View

Seshadri S, Fitzpatrick A, Ikram M, DeStefano A, Gudnason V, Boada M . Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010; 303(18):1832-40. PMC: 2989531. DOI: 10.1001/jama.2010.574. View

10.

St George-Hyslop P, McLachlan D, Tsuda T, Rogaev E, Karlinsky H, Lippa C . Alzheimer's disease and possible gene interaction. Science. 1994; 263(5146):537. DOI: 10.1126/science.8290965. View

11.

Bennett D, Schneider J, Arvanitakis Z, Kelly J, Aggarwal N, Shah R . Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006; 66(12):1837-44. DOI: 10.1212/01.wnl.0000219668.47116.e6. View

12.

Lee J, Barral S, Cheng R, Chacon I, Santana V, Williamson J . Age-at-onset linkage analysis in Caribbean Hispanics with familial late-onset Alzheimer's disease. Neurogenetics. 2007; 9(1):51-60. PMC: 2701253. DOI: 10.1007/s10048-007-0103-3. View

13.

Pritchard J, Stephens M, Donnelly P . Inference of population structure using multilocus genotype data. Genetics. 2000; 155(2):945-59. PMC: 1461096. DOI: 10.1093/genetics/155.2.945. View

14.

Green R, Cupples L, Go R, Benke K, Edeki T, Griffith P . Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002; 287(3):329-36. DOI: 10.1001/jama.287.3.329. View

15.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

16.

McCauley J, Hahs D, Jiang L, Scott W, Welsh-Bohmer K, Jackson C . Combinatorial Mismatch Scan (CMS) for loci associated with dementia in the Amish. BMC Med Genet. 2006; 7:19. PMC: 1448207. DOI: 10.1186/1471-2350-7-19. View

17.

Scott W, Nance M, Watts R, Hubble J, Koller W, Lyons K . Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001; 286(18):2239-44. DOI: 10.1001/jama.286.18.2239. View

18.

Beecham G, Martin E, Li Y, Slifer M, Gilbert J, Haines J . Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009; 84(1):35-43. PMC: 2668056. DOI: 10.1016/j.ajhg.2008.12.008. View

19.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

20.

Cobb J, Wolf P, Au R, White R, DAgostino R . The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology. 1995; 45(9):1707-12. DOI: 10.1212/wnl.45.9.1707. View